Table 4. Echocardiography at age 10 weeks in mice crossed with transgenic overexpressors of Tnnt2 mRNA (TGWT) or phospholamban knockout (Pln-/-) mice.
| No. of mice | LVWT (mm) | LVEDD (mm) | LVESD (mm) | FS (%) | HR (bpm) | |
|---|---|---|---|---|---|---|
| Tnnt2+/+ (WT) | 35 | 0.77 ± 0.02 | 3.54 ± 0.06 | 2.33 ± 0.06 | 34 ± 1 | 424 ± 9 |
| TGWT | 7 | 0.74 ± 0.03 | 3.53 ± 0.12 | 2.16 ± 0.12 | 39 ± 2 | 398 ± 18 |
| Pln-/- | 8 | 0.93 ± 0.06 | 2.92 ± 0.12 | 1.31 ± 0.13 | 56 ± 3 | 532 ± 16 |
| Tnnt2R141W/+ | 51 | 0.66 ± 0.02 * | 3.92 ± 0.06 * | 3.00 ± 0.07 * | 24 ± 1 * | 428 ± 7 |
| Tnnt2R141W/+/TGWT | 4 | 0.67 ± 0.09 | 3.18 ± 0.26 *,† | 2.21 ± 0.40 † | 32 ± 8 † | 378 ± 14 |
| Tnnt2R141W/+/Pln-/- | 18 | 0.75 ± 0.03 | 3.94 ± 0.12 | 2.98 ± 0.15 * | 25 ± 2 * | 486 ± 10 |
LVWT, left ventricular wall thickness at end diastole; LVEDD, left ventricular end diastolic diameter; FS, fractional shortening; HR, heart rate; bpm, beats per minute; WT, wildtype. P<0.01 by ANOVA and Bonferroni correction versus
*WT
†Tnnt2R141W/+.